The topoisomerase II catalytic inhibitor ICRF-193 preferentially targets telomeres that are capped by TRF2

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 5, 2015, Pages C372-C377

  Chen, Lianxiang ^a   Zhu, Xiaowei ^a   Zou, Yaru ^a   Xing, Jun ^a   Gilson, Eric ^a,b,c   Lu, Yiming ^a   Ye, Jing ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

ICRF 193; POT1; Telomere; Topoisomerase II; TRF2

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; BLEOMYCIN; DNA; TELOMERASE INHIBITOR; TELOMERIC REPEAT BINDING FACTOR 2; 4,4'-(1,2-DIMETHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONE; GYRASE INHIBITOR; PIPERAZINE DERIVATIVE; TERF2 PROTEIN, HUMAN;

ARTICLE; BASE PAIRING; CELL PROTECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; DNA PROBE; DRUG MECHANISM; DRUG TARGETING; FIBROSARCOMA CELL LINE; HT1080 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; TELOMERE; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA DAMAGE; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HUMANS; PIPERAZINES; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 2; TOPOISOMERASE II INHIBITORS;

EID: 84923925755     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00321.2014     Document Type: Article

References (19)

1. Amiard S, Doudeau M, Pinte S, Poulet A, Lenain C, Faivre- Moskalenko C, Angelov D, Hug N, Vindigni A, Bouvet P, Paoletti J, Gilson E, Giraud-Panis MJ. A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol 14: 147–154, 2007.
2. Bae NS, Baumann P. A RAP1/TRF2 complex inhibits nonhomologous end-joining at human elomeric DNA ends. Mol Cell 26: 323–334, 2007.
3. Bilaud T, Brun C, Ancelin K, Koering CE, Laroche T, Gilson E. Telomeric localization of TRF2, a novel human telobox protein. Nat Genet 17: 236–239, 1997.
4. Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lepinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londono-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol 15: 818–828, 2013.
5. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 12: 1133–1138, 2006.
6. Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev 21: 206–220, 2007.
7. Brunori M, Gilson E. [Telomere and cancer: what’s more at the end?]. Med Sci (Paris) 21: 37–42, 2005.
8. Cech TR. Beginning to understand the end of the chromosome. Cell 116: 273–279, 2004.
9. Celli GB, Denchi EL, de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 8: 885–890, 2006.
10. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM, Johnson RT. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372: 467–470, 1994.
11. Giraud-Panis MJ, Pisano S, Benarroch-Popivker D, Pei B, Le Du MH, Gilson E. One identity or more for telomeres? Front Oncol 3: 48, 2013.
12. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell 97: 503–514, 1999.
13. Lu Y, Leong W, Guerin O, Gilson E, Ye J. Telomeric impact of conventional chemotherapy. Front Med 7: 411–417, 2013.
14. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E, Koering CE, Gilson E. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res 9: 1105–1111, 2003.
15. Okamoto K, Bartocci C, Ouzounov I, Diedrich JK, Yates JR 3rd, Denchi EL. A two-step mechanism for TRF2-mediated chromosome-end protection. Nature 494: 502–505, 2013.
16. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28: 155–159, 2001.
17. Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens MF, D’Incalci M, Blasco M, Chiorino G, Bauwens S, Horard B, Gilson E, Stoppacciaro A, Zupi G, Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest 117: 3236–3247, 2007.
18. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 92: 401–413, 1998.
19. Ye J, Lenain C, Bauwens S, Rizzo A, Saint-Leger A, Poulet A, Benarroch D, Magdinier F, Morere J, Amiard S, Verhoeyen E, Britton S, Calsou P, Salles B, Bizard A, Nadal M, Salvati E, Sabatier L, Wu Y, Biroccio A, Londono-Vallejo A, Giraud-Panis MJ, Gilson E. TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell 142: 230–242, 2010.